Registro:

Referencias:

• McCarthy, E.F., The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas (2006) Iowa Orthop. J., 26, pp. 154-158
• Carswell, E.A., Old, L.J., Kassel, R.L., Green, S., Fiore, N., Williamson, B., An endotoxin-induced serum factor that causes necrosis of tumors (1975) Proc. Natl. Acad. Sci. USA, 72, pp. 3666-3670
• Bahia, M.S., Silakari, O., Tumor necrosis factor alpha converting enzyme: An encouraging target for various inflammatory disorders (2010) Chem. Biol. Drug des, 75, pp. 415-443
• Pennica, D., Nedwin, G.E., Hayflick, J.S., Seeburg, P.H., Derynck, R., Palladino, M.A., Kohr, W.J., Goeddel, D.V., Human tumour necrosis factor: Precursor structure, expression and homology to lymphotoxin (1984) Nature, 312, pp. 724-729
• Wang, H., Czura, C., Chargaff, E., Tumor necrosis factor (2003) The Cytokine Handbook, 2, pp. 837-860. , Thomson, A.W. Lotze, M.T. Eds. Elsevier
• Van Horssen, R., Ten Hagen, T.L.M., Eggermont, A.M.M., TNF-alpha in cancer treatment: Molecular insights, antitumor effects, and clinical utility (2006) Oncologist, 11, pp. 397-408
• Black, R.A., Rauch, C.T., Kozlosky, C.J., Peschon, J.J., Slack, J.L., Wolfson, M.F., Castner, B.J., Cerretti, D., A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells (2007) Nature, 20, pp. 729-733
• Hikita, A., Tanaka, N., Yamane, S., Ikeda, Y., Furukawa, H., Tohma, S., Suzuki, R., Fukui, N., Involvement of a disintegrin and metalloproteinase 10 and 17 in shedding of tumor necrosis factor-alpha (2009) Biochem. Cell Biol, 87, pp. 581-593
• Haro, H., Crawford, H.C., Fingleton, B., Shinomiya, K., Spengler, D.M., Matrisian, L.M., Matrix metalloproteinase- 7 - dependent release of tumor necrosis factor-α in a model of herniated disc resorption (2000) J. Clin. Invest, 105, pp. 143-150
• Becker-Pauly, C., Rose-John, S., TNFα cleavage beyond TACE/ADAM17: Matrix metalloproteinase 13 is a potential therapeutic target in sepsis and colitis (2013) EMBO Mol. Med, 5, pp. 902-904
• Puimege, L., Libert, C., Hauwermeiren, F.V., Cytokine & growth factor reviews regulation and dysregulation of tumor necrosis factor receptor-1 (2014) Cytokine Growth Factor Rev, 25, pp. 285-300
• Pimentel-Muinos, F.X., Seed, B., Regulated commitment of TNF receptor signaling: A molecular switch for death or activation (1999) Immunity, 11, pp. 783-793
• Aggarwal, B., Signalling pathways of the TNF superfamily: A double-edged sword (2003) Nat. Rev. Immunol., 3, pp. 745-756
• Locksley, R.M., Killeen, N., Lenardo, M.J., The TNF and TNF receptor superfamilies (2001) Cell, 104, pp. 487-501
• Bodmer, J.-L., Schneider, P., Tschopp, J., The molecular architecture of the TNF superfamily (2002) Trends Biochem. Sci., 27, pp. 19-26
• Chen, G., Goeddel, D.V., TNF-R1 signaling: A beautiful pathway (2002) Science, 296, pp. 1634-1635
• Wajant, H., Pfizenmaier, K., Scheurich, P., Tumor necrosis factor signaling (2003) Cell Death Differ, pp. 45-65
• Keller, M., Mazuch, J., Abraham, U., Eom, G.D., Herzog, E.D., Volk, H.-D., Kramer, A., Maier, B., A circadian clock in macrophages controls inflammatory immune responses (2009) Proc. Natl. Acad. Sci. USA, 106, pp. 21407-21412
• Van Linthout, S., Miteva, K., Tschope, C., Crosstalk between fibroblasts and inflammatory cells (2014) Cardiovasc. Res, 102, pp. 258-269
• Cessak, G., Kuzawinska, O., Burda, A., Lis, K., Wojnar, M., Mirowska-Guzel, D., Bałkowiec-Iskra, E., TNF inhibitors - Mechanisms of action, approved and off-label indications (2014) Pharmacol. Rep., 66, pp. 836-844
• Eck, M.J., Sprang, S.R., The structure of tumor necrosis factor-α at 2.6 A resolution. Implications for receptor binding (1989) J. Biol. Chem, 264, pp. 17595-17605
• Palladino, M.A., Bahjat, F.R., Theodorakis, E.A., Moldawer, L.L., Anti-TNF-α therapies: The next generation (2003) Nat. Rev. Drug Discov, 2, pp. 736-746
• Sfikakis, P.P., Tsokos, G.C., Towards the next generation of anti-TNF drugs (2011) Clin. Immunol, 141, pp. 231-235
• Sfikakis, P.P., The first decade of biologic TNF antagonists in clinical practice: Lessons learned, unresolved issues and future directions (2010) Curr. Dir. Autoimmun, 11, pp. 180-210
• Lin, J., Ziring, D., Desai, S., Kim, S., Wong, M., Korin, Y., Reed, E., Singh, R.R., TNFalpha blockade in human diseases: An overview of efficacy and safety (2009) Clin Immunol, 126, pp. 13-30
• Listing, J., Strangfeld, A., Kary, S., Rau, R., Von Hinueber, U., Stoyanova-Scholz, M., Gromnica-Ihle, E., Zink, A., Infections in patients with rheumatoid arthritis treated with biologic agents (2005) Arthritis Rheum, 52, pp. 3403-3412
• Schon, A., Lam, S.Y., Freire, E., Thermodynamics-based drug design: Strategies for inhibiting protein-protein interactions (2011) Future Med. Chem, 3, pp. 1129-1137
• Arkin, M.R., Wells, J.A., Small-molecule inhibitors of protein-protein interactions: Progressing towards the dream (2004) Nat. Rev. Drug Discov, 3, pp. 301-317
• Murumkar, P.R., Giridhar, R., Yadav, M.R., Novel methods and strategies in the discovery of TACE inhibitors (2013) Expert Opin. Drug Discov, 8, pp. 157-181
• Sipos, W., Pietschmann, P., Rauner, M., Strategies for novel therapeutic approaches targeting cytokines and signaling pathways of osteoclasto- And osteoblastogenesis in the fight against immune-mediated bone and joint diseases (2008) Curr. Med. Chem, 15, pp. 127-136
• Debnath, T., Kim, D., Lim, B., Natural products as a source of anti-inflammatory agents associated with inflammatory bowel disease (2013) Molecules, 18, pp. 7253-7270
• Venkatesha, S., Dudics, S., Acharya, B., Moudgil, K., Cytokine-modulating strategies and newer cytokine targets for arthritis therapy (2014) Int. J. Mol. Sci, 16, pp. 887-906
• Bhandari, P., Patel, N.K., Gangwal, R.P., Sangamwar, A.T., Bhutani, K.K., Oleanolic acid analogs as NO, TNF-α and IL-1β inhibitors: Synthesis, biological evaluation and docking studies (2014) Bioorg. Med. Chem. Lett., 24, pp. 4114-4119
• Bhandari, P., Patel, N.K., Bhutani, K.K., Synthesis of new heterocyclic lupeol derivatives as nitric oxide and proinflammatory cytokine inhibitors (2014) Bioorg. Med. Chem. Lett., 24, pp. 3596-3599
• Campana, P.R.V., Coleman, C.M., Teixeira, M.M., Ferreira, D., Braga, F.C., TNF-α inhibition elicited by mansoins A and B, heterotrimeric flavonoids isolated from mansoa hirsuta (2014) J. Nat. Prod, 77, pp. 824-830
• Chaulet, C., Croix, C., Alagille, D., Normand, S., Delwail, A., Favot, L., Lecron, J.-C., Viaud-Massuard, M.-C., Design, synthesis and biological evaluation of new thalidomide analogues as TNF-α and IL-6 production inhibitors (2011) Bioorg. Med. Chem. Lett, 21, pp. 1019-1022
• Choi, S., Nguyen, V.T., Tae, N., Lee, S., Ryoo, S., Min B.-., S., Lee, J.H., Anti-inflammatory and heme oxygenase-1 inducing activities of lanostane triterpenes isolated from mushroom Ganoderma lucidum in RAW264.7 cells (2014) Toxicol. Appl. Pharmacol, 280, pp. 434-442
• Dhuru, S., Bhedi, D., Gophane, D., Hirbhagat, K., Nadar, V., More, D., Parikh, S., Sivaramakrishnan, H., Novel diarylheptanoids as inhibitors of TNF-α production (2011) Bioorg. Med. Chem. Lett., 21, pp. 3784-3787
• Guirado, A., Lopez Sanchez, J.I., Ruiz-Alcaraz, A.J., Bautista, D., Galvez, J., Synthesis and biological evaluation of 4-alkoxy-6, 9-dichloro [1, 2, 4] triazolo [4, 3-a]quinoxalines as inhibitors of TNF-α and IL-6 (2012) Eur. J. Med. Chem, 54, pp. 87-94
• Guirado, A., Lopez Sanchez, J.I., Ruiz-Alcaraz, A.J., Garcia-Penarrubia, P., Bautista, D., Galvez, J., First synthesis and biological evaluation of 4-amino-2-aryl-6, 9- dichlorobenzo [g] pteridines as inhibitors of TNF-α and IL-6 (2013) Eur. J. Med. Chem, 66, pp. 269-275
• Liu, Q., Shu, X., Wang, L., Sun, A., Liu, J., Cao, X., Albaconol, a plant-derived small molecule, inhibits macrophage function by suppressing NF-kappaB activation and enhancing SOCS1 expression (2008) Cell. Mol. Immunol., 5, pp. 271-278
• Kim, J.I., Lee, H.Y., Park, K.S., Lee, T., Ryu, S.H., Bae, Y.-S., A small compound that inhibits lipopolysaccharideinduced tumor necrosis factor-alpha production (2006) Biochem. Biophys. Res. Commun., 347, pp. 797-802
• Luo, W., Yu, Q., Salcedo, I., Holloway, H.W., Lahiri, D.K., Brossi, A., Tweedie, D., Greig, N.H., Design, synthesis and biological assessment of novel N-substituted 3- (phthalimidin-2-yl)-2, 6-dioxopiperidines and 3-substituted 2, 6-dioxopiperidines for TNF-α inhibitory activity (2011) Bioorg. Med. Chem, 19, pp. 3965-3972
• Ottosen, E.R., Sorensen, M.D., Bjorkling, F., Skak-Nielsen, T., Fjording, M.S., Aaes, H., Binderup, L., Synthesis and structure-activity relationship of aminobenzophenones. A novel class of p38 MAP kinase inhibitors with high antiinflammatory activity (2003) J. Med. Chem, 46, pp. 5651-5662
• Vančo, J., Galikova, J., Hošek, J., Dvorak, Z., Parakova, L., Travniček, Z., Gold(I) Complexes of 9-Deazahypoxanthine as Selective Antitumor and Anti-Inflammatory Agents (2014) PLoS One, 9, p. e109901
• Shah, M.R., Arfan, M., Amin, H., Hussain, Z., Qadir, M.I., Choudhary, M.I., VanDerveer, D., Khan, I.U., Synthesis of new bergenin derivatives as potent inhibitors of inflammatory mediators NO and TNF-α (2012) Bioorg. Med. Chem. Lett, 22, pp. 2744-2747
• Gaggeri, R., Rossi, D., Christodoulou, M.S., Passarella, D., Leoni, F., Azzolina, O., Collina, S., Chiral flavanones from Amygdalus lycioides spach: Structural elucidation and identification of TNFalpha inhibitors by bioactivity-guided fractionation (2012) Molecules, 17, pp. 1665-1674
• Aggarwal, B.B., Gupta, S.C., Sung, B., Curcumin: An orally bioavailable blocker of TNF and other pro-inflammatory biomarkers (2013) Br. J. Pharmacol, 169, pp. 1672-1692
• Meng, Z., Yan, C., Deng, Q., Gao, D., Niu, X., Curcumin inhibits LPS-induced inflammation in rat vascular smooth muscle cells in vitro via ROS-relative TLR4-MAPK/NF-κB pathways (2013) Acta Pharmacol. Sin., 34, pp. 901-911
• Tunon, M.J., Garcia-Mediavilla, M.V., Sanchez-Campos, S., Gonzalez-Gallego, J., Potential of flavonoids as antiinflammatory agents: Modulation of pro-inflammatory gene expression and signal transduction pathways (2009) Curr. Drug Metab, 10, pp. 256-271
• Balasubramanyam, K., Varier, R.A., Altaf, M., Swaminathan, V., Siddappa, N.B., Ranga, U., Kundu, T.K., Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferasedependent chromatin transcription (2004) J. Biol. Chem, 279, pp. 51163-51171
• Singh, S., Aggarwal, B.B., Activation of transcription factor NF-kB is suppressed by curcumin (diferuloylmethane) (1995) J. Biol. Chem, 270, pp. 24995-25000
• Reuter, S., Gupta, S.C., Park, B., Goel, A., Aggarwal, B.B., Epigenetic changes induced by curcumin and other natural compounds (2011) Genes Nutr, 6, pp. 93-108
• Tu, C., Han, B., Yao, Q., Zhang, Y., Liu, H., Zhang, S., Curcumin attenuates Concanavalin A-induced liver injury in mice by inhibition of Toll-like receptor (TLR) 2, TLR4 and TLR9 expression (2012) Int. Immunopharmacol, 12, pp. 151-157
• Kumar, A., Dhawan, S., Hardegen, N.J., Aggarwal, B.B., Curcumin (Diferuloylmethane) inhibition of tumor necrosis factor (TNF)-mediated adhesion of monocytes to endothelial cells by suppression of cell surface expression of adhesion molecules and of nuclear factor-kappaB activation (1998) Biochem. Pharmacol., 55, pp. 775-783
• Zhou, T., Hou, J., Wang, M., Ma, L., Wu, L., Wang, S., Sun, B., Yao, Z., Regio-controlled synthesis of unsymmetrical pyrazine-fused sinomenine derivatives and discriminate substitution effects on TNF-α inhibitory activity (2014) Tetrahedron, 70, pp. 5475-5482
• Upadhyay, K., Bavishi, A., Thakrar, S., Radadiya, A., Vala, H., Parekh, S., Bhavsar, D., Shah, A., Synthesis and biological evaluation of 4-styrylcoumarin derivatives as inhibitors of TNF-α and IL-6 with anti-tubercular activity (2011) Bioorg. Med. Chem. Lett., 21, pp. 2547-2549
• Ramirez, J.A., Bruttomesso, A.C., Michelini, F.M., Acebedo, S.L., Alche, L.E., Galagovsky, L.R., Syntheses of immunomodulating androstanes and stigmastanes: Comparison of their TNF-α inhibitory activity (2007) Bioorganic Med. Chem, 15, pp. 7538-7544
• Michelini, F.M., Berra, A., Alche, L.E., The in vitro immunomodulatory activity of a synthetic brassinosteroid analogue would account for the improvement of herpetic stromal keratitis in mice (2008) J. Steroid Biochem. Mol. Biol., 108, pp. 164-170
• Michelini, F.M., Zorrilla, P., Robello, C., Alche, L.E., Immunomodulatory activity of an anti-HSV-1 synthetic stigmastane analog (2013) Bioorganic Med. Chem, 21, pp. 560-568
• Spilker, B., FritzSimmons, S., Horan, M., US drug and biologic approvals in 1998 (1999) Drug Dev. Res, 48, pp. 139-153
• Tseng, S., Pak, G., Washenik, K., Pomeranz, M.K., Shupack, J.L., Rediscovering thalidomide: A review of its mechanism of action, side effects, and potential uses (1996) J. Am. Acad. Dermatol, 35, pp. 969-979
• Moreira, A.L., Sampaio, E.P., Zmuidzinas, A., Frindt, P., Smith, K.A., Kaplan, G., Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation (1993) J. Exp. Med, 177, pp. 1675-1680
• Sampaio, E.P., Sarno, E.N., Galilly, R., Cohn, Z.A., Kaplan, G., Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes (1991) J. Exp. Med., 173, pp. 699-703
• Revesz, L., Blum, E., Di Padova, F.E., Buhl, T., Feifel, R., Gram, H., Hiestand, P., Rucklin, G., SAR of benzoylpyridines and benzophenones as p38alpha MAP kinase inhibitors with oral activity (2004) Bioorg. Med. Chem. Lett., 14, pp. 3601-3605
• Gururaja, T.L., Yung, S., Ding, R., Huang, J., Zhou, X., McLaughlin, J., Daniel-Issakani, S., Kinoshita, T., A class of small molecules that inhibit TNF alpha-induced survival and death pathways via prevention of interactions between TNFalphaRI, TRADD, and RIP1 (2007) Chem. Biol, 14, pp. 1105-1118
• King, M.D., Alleyne, C.H., Dhandapani, K.M., TNF-alpha receptor antagonist, R-7050, improves neurological outcomes following intracerebral hemorrhage in mice (2013) Neurosci. Lett, 542, pp. 92-96
• Aeluri, M., Chamakuri, S., Dasari, B., Guduru, S.K.R., Jimmidi, R., Jogula, S., Arya, P., Small molecule modulators of protein-protein interactions: Selected case studies (2014) Chem. Rev., 114, pp. 4640-4694
• Milroy, L.-G., Grossmann, T.N., Hennig, S., Brunsveld, L., Ottmann, C., Modulators of protein-protein interactions (2014) Chem. Rev., 114, pp. 4695-4748
• London, N., Raveh, B., Schueler-Furman, O., Druggable protein-protein interactions-from hot spots to hot segments (2013) Curr. Opin. Chem. Biol, 17, pp. 952-959
• Sheinerman, F.B., Honig, B., On the role of electrostatic interactions in the design of protein-protein interfaces (2002) J. Mol. Biol, 318, pp. 161-177
• Levy, E.D., A simple definition of structural regions in proteins and its use in analyzing interface evolution (2010) J. Mol. Biol, 403, pp. 660-670
• Grazioli, L., Alzani, R., Ciomei, M., Mariani, M., Restivo, A., Cozzi, E., Marcucci, F., Inhibitory effect of suramin on receptor binding and cytotoxic activity of tumor necrosis factor alpha (1992) Int. J. Immunopharmacol, 14, pp. 637-642
• Alzani, R., Corti, A., Grazioli, L., Cozzi, E., Ghezzi, P., Marcucci, F., Suramin induces deoligomerization of human tumor necrosis factor alpha (1993) J. Biol. Chem, 268, pp. 12526-12529
• Mancini, F., Toro, C.M., Mabilia, M., Giannangeli, M., Pinza, M., Milanese, C., Inhibition of tumor necrosis factoralpha (TNF-alpha)/TNF-alpha receptor binding by structural analogues of suramin (1999) Biochem. Pharmacol, 58, pp. 851-859
• He, M.M., Smith, A.S., Oslob, J.D., Flanagan, W.M., Braisted, A.C., Whitty, A., Cancilla, M.T., Cunningham, B.C., Small-molecule inhibition of TNF-alpha (2005) Science, 310, pp. 1022-1025
• Keerthy, H.K., Mohan, C.D., Siveen, K.S., Fuchs, J.E., Rangappa, S., Sundaram, M.S., Li, F., Rangappa, K.S., Novel synthetic biscoumarins target tumor necrosis factor- in hepatocellular carcinoma in vitro and in vivo (2014) J. Biol. Chem., 289, pp. 31879-31890
• Chan, D.S., Lee, H.M., Yang, F., Che, C.M., Wong, C.C., Abagyan, R., Leung, C.H., Ma, D.L., Structure-based discovery of natural-product-like TNF-α inhibitors (2010) Angew. Chem. Int. Ed. Engl., 49, pp. 2860-2864
• Choi, H., Lee, Y., Park, H., Oh, D.-S., Discovery of the inhibitors of tumor necrosis factor alpha with structurebased virtual screening (2010) Bioorg. Med. Chem. Lett, 20, pp. 6195-6198
• Leung, C.H., Chan, D.S.H., Kwan, M.H.T., Cheng, Z., Wong, C.Y., Zhu, G.Y., Fong, W.F., Ma, D.L., Structurebased repurposing of FDA-approved drugs as TNF-α inhibitors (2011) Chem. Med. Chem., 6, pp. 765-768
• Abrams, P., Andersson, K.-E., Muscarinic receptor antagonists for overactive bladder (2007) BJU Int, 100, pp. 987-1006
• Bays, H.E., Ose, L., Fraser, N., Tribble, D.L., Quinto, K., Reyes, R., Johnson-Levonas, A.O., Donahue, S.R., A multicenter, randomized, double-blind, placebocontrolled, factorial design study to evaluate the lipidaltering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia (2004) Clin. Ther., 26, pp. 1758-1773
• Shen, Q., Chen, J., Wang, Q., Deng, X., Liu, Y., Lai, L., Discovery of highly potent TNFα inhibitors using virtual screen (2014) Eur. J. Med. Chem, 85, pp. 119-126
• Leung, C.H., Zhong, H.J., Yang, H., Cheng, Z., Chan, D.S.H., Ma, V.P.Y., Abagyan, R., Ma, D.L., A metal-based inhibitor of tumor necrosis factor-α (2012) Angew. Chem. Int. Ed. Engl., 51, pp. 9010-9014
• Haider, S., Alam, M.S., Hamid, H., Shafi, S., Nargotra, A., Mahajan, P., Nazreen, S., Panda, A.K., Synthesis of novel 1, 2, 3-triazole based benzoxazolinones: Their TNF-α based molecular docking with in-vivo anti-inflammatory, antinociceptive activities and ulcerogenic risk evaluation (2013) Eur. J. Med. Chem., 70, pp. 579-588
• Kumar, K.S., Kumar, P.M., Kumar, K.A., Sreenivasulu, M., Jafar, A.A., Rambabu, D., Krishna, G.R., Pal, M., A new three-component reaction: Green synthesis of novel isoindolo [2, 1-a]quinazoline derivatives as potent inhibitors of TNF-α (2011) Chem. Commun. (Camb)., 47, pp. 5010-5012
• Kim, Y., Hong, Y.D., Joo, Y.H., Woo, B.Y., Kim, S.-Y., Koh, H.J., Park, M., Shin, S.S., Synthesis and structure-activity relationship of cyclopentenone oximes as novel inhibitors of the production of tumor necrosis factor- α (2014) Bioorg Med. Chem. Lett., 24, pp. 2-5
• Semmler, J., Wachtel, H., Endres, S., The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-alpha production by human mononuclear cells (1993) Int. J. Immunopharmacol., 15, pp. 409-413
• Lian, W., Upadhyaya, P., Rhodes, C.A., Liu, Y., Pei, D., Screening bicyclic peptide libraries for protein-protein interaction inhibitors: Discovery of a tumor necrosis factor-α Antagonist (2013) J. Am. Chem. Soc., 135, pp. 11990-11995
• Hu, Z., Qin, J., Zhang, H., Wang, D., Hua, Y., Ding, J., Shan, L., Zhang, W., Japonicone A antagonizes the activity of TNF-α by directly targeting this cytokine and selectively disrupting its interaction with TNF receptor-1 (2012) Biochem. Pharmacol, 84, pp. 1482-1491
• Ma, L., Gong, H., Zhu, H., Ji, Q., Su, P., Liu, P., Cao, S., Xu, Y., A novel small-molecule tumor necrosis factor α inhibitor attenuates inflammation in a hepatitis mouse model (2014) J. Biol. Chem, 289, pp. 12457-12466
• Saito, H., Kojima, T., Takahashi, M., Horne, W.C., Baron, R., Amagasa, T., Ohya, K., Aoki, K., A tumor necrosis factor receptor loop peptide mimic inhibits bone destruction to the same extent as anti-tumor necrosis factor monoclonal antibody in murine collagen-induced arthritis (2007) Arthritis Rheum., 56, pp. 1164-1174
• Bongartz, T., Sutton, A.J., Sweeting, M.J., Buchan, I., Matteson, E.L., Montori, V., Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials (2006) JAMA, 295, pp. 2275-2285
• Gardam, M.A., Keystone, E.C., Menzies, R., Manners, S., Skamene, E., Long, R., Vinh, D.C., Anti-tumour necrosis factor agents and tuberculosis risk: Mechanisms of action and clinical management (2003) Lancet Infect. Dis., 3, pp. 148-155
• Bluml, S., Scheinecker, C., Smolen, J.S., Redlich, K., Targeting TNF receptors in rheumatoid arthritis (2012) Int. Immunol., 24, pp. 275-281
• Zettlitz, K.A., Lorenz, V., Landauer, K., Munkel, S., Herrmann, A., Scheurich, P., Pfizenmaier, K., Kontermann, R.E., ATROSAB, a humanized antagonistic anti-tumor necrosis factor receptor one-specific antibody (2010) MAbs, 2, pp. 639-647
• Shibata, H., Yoshioka, Y., Abe, Y., Ohkawa, A., Nomura, T., Minowa, K., Mukai, Y., Tsutsumi, Y., The treatment of established murine collagen-induced arthritis with a TNFR1-selective antagonistic mutant TNF (2009) Biomaterials, 30, pp. 6638-6647
• Arntz, O.J., Geurts, J., Veenbergen, S., Bennink, M.B., Van Den Brand, B.T., Abdollahi-Roodsaz, S., Van Den Berg, W.B., Van De Loo, F.A., A crucial role for tumor necrosis factor receptor 1 in synovial lining cells and the reticuloendothelial system in mediating experimental arthritis (2010) Arthritis Res. Ther., 12, p. R61
• Huang, X.W., Yang, J., Dragovic, A.F., Zhang, H., Lawrence, T.S., Zhang, M., Antisense oligonucleotide inhibition of tumor necrosis factor receptor 1 protects the liver from radiation-induced apoptosis (2006) Clin. Cancer Res., 12, pp. 2849-2855
• Van Hauwermeiren, F., Vandenbroucke, R.E., Libert, C., Treatment of TNF mediated diseases by selective inhibition of soluble TNF or TNFR1 (2011) Cytokine Growth Factor Rev., 22, pp. 311-319
• Murali, R., Cheng, X., Berezov, A., Du, X., Schon, A., Freire, E., Xu, X., Greene, M.I., Disabling TNF receptor signaling by induced conformational perturbation of tryptophan-107 (2005) Proc. Natl. Acad. Sci. USA, 102, pp. 10970-10975
• He, M.M., Smith, A.S., Oslob, J.D., Flanagan, W.M., Braisted, A.C., Whitty, A., Cancilla, M.T., Cunningham, B.C., Small-molecule inhibition of TNF-alpha (2005) Science, 310, pp. 1022-1025
• Carter, P.H., Scherle, P.A., Muckelbauer, J.K., Voss, M.E., Liu, R.Q., Thompson, L.A., Tebben, A.J., Muckelbauer, J.A., Photochemically enhanced binding of small molecules to the tumor necrosis factor receptor-1 inhibits the binding of TNF-alpha (2001) Proc. Natl. Acad. Sci. USA, 98, pp. 11879-11884
• Probert, L., TNF and its receptors in the CNS: The essential, the desirable and the deleterious effects (2015) Neuroscience, (15), pp. 00579-00585. , S0306-S4522

Citas:

---------- APA ----------

---------- CHICAGO ----------

---------- MLA ----------

---------- VANCOUVER ----------